Morphin 30 Retard (Morphine Sulfate)

Morphine sulfate acts as an agonist at mu‑opioid receptors in the brain and spinal cord. Activation of these receptors inhibits the release of excitatory neurotransmitters, decreasing neuronal firing and altering the perception of pain, while also producing sedation.

The dose of Morphin 30 Retard is individualized. A qualified prescriber determines the appropriate starting dose and titration schedule based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and overall clinical condition.

Safety data are limited. Morphine crosses the placenta and is excreted in breast milk, so it should be used during pregnancy or lactation only when the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Morphin 30 Retard provides a prolonged‑release profile, allowing once‑ or twice‑daily dosing, which can improve adherence compared with immediate‑release opioids that require more frequent dosing. Its potency is comparable to other strong opioids such as oxycodone, but conversion to equivalent doses must follow established opioid‑conversion guidelines.

Store Morphin 30 Retard at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct light, and ensure they are out of reach of children and unauthorized personnel.

Morphin 30 Retard is intended for oral administration. Swallow the tablet whole with a full glass of water; do not crush, chew, or split the tablet, as this can compromise the extended‑release mechanism and increase the risk of overdose.

The most serious risks include respiratory depression, severe hypotension, profound sedation, and the potential for physical dependence or addiction. Patients should be monitored closely for signs of respiratory compromise, especially during dose initiation or after dose adjustments.

Morphin 30 Retard is contraindicated in patients with known hypersensitivity to morphine or any component of the formulation, in those with significant respiratory depression, acute or severe bronchial asthma, or in patients who have taken monoamine oxidase inhibitors within the past 14 days.